COMP <GO>
NNVC vs IBO // EV/EBITDA & P/E VALUATION
NanoViricides Inc. (NYSE) VS. Impact BioMedical Inc. (NYSE) • 15-METRIC TALLY: NNVC 2
— IBO 2
■ METRIC PARITY
LAST: $1.35 (+1.50%) • MKT CAP: $34.0M
valuation
—
LAST: $4.01 (+5.53%) • MKT CAP: $32.5M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NNVC VS. IBO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NNVC | IBO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | -30.00% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -27.50% | -7.50 | IBO | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -23.37% | -5.72% | -17.65 | IBO | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 5.88 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 2/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.3 | 43.6 | +3.70 | NNVC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $34.0M | $32.5M | $1.5M | NNVC | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NNVC REV | IBO REV | NNVC GROSS % | IBO GROSS % | NNVC FCF | IBO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $26.9M | $32.0K | — | -50.0% | -$8.5M | -$1.9M |
| FY 2024 | $23.8M | $80.5M | — | — | -$6.5M | -$2.9M |
| FY 2023 | $25.0M | $11.3M | — | — | -$5.7M | -$2.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NNVC // BETA —
IBO // BETA —